Hypofractionated-intensity modulated radiotherapy (hypo-IMRT) and temozolomide (TMZ) with or without bevacizumab ( XXXX ) for newly diagnosed @entity463 ( @entity463 ): a comparison of two prospective phase II trials.

@entity1 @entity5 @entity1493 @entity463 @entity1349
To compare progression-free (PFS) and @entity1349 ( @entity1349 ) in @entity1 treated in two consecutive phase II trials of hypofractionated-intensity modulated radiotherapy (hypo-IMRT) and temozolomide (TMZ) with or without bevacizumab ( @entity1493 ). @entity1 with newly diagnosed @entity463 ( @entity463 ) after biopsy or resection were enrolled on a clinical trial with hypo-IMRT and TMZ (hypo-IMRT/TMZ alone) from 2008 to 2010, or in the second protocol with the same hypo-IMRT and TMZ plus @entity1493 (hypo-IMRT/TMZ/ @entity1493 ) from 2010 to 2013. All @entity1 received postoperative hypo-IMRT to the surgical @entity5 plus margin to a total dose of 60  Gy and to the T2 abnormality with margin to 30  Gy, both in ten fractions. Concurrent TMZ (75  mg/m(2)/day) was given to all @entity1 for 28 consecutive days followed by adjuvant TMZ (150-200  mg/m(2)/day). @entity1 enrolled on the hypo-IMRT/TMZ/ @entity1493 trial received concurrent and adjuvant @entity1493 (10  mg/kg) on days 1 and 15 of each 28-day cycle. Hazard ratios of PFS and @entity1349 were compared between trials in a Cox proportional hazards model. Twenty-six @entity1 were enrolled on the hypo-IMRT/TMZ alone trial and 30 @entity1 on the hypo-IMRT/TMZ/ @entity1493 trial. Median follow-up was 13.9 and 14.7  months, respectively. Median PFS was 3.4  months longer with hypo-IMRT/TMZ/ @entity1493 but the difference was not statistically significant (12.8 vs. 9.4  months, p  =  0.58). Median ( @entity1349 ) was 16.3  months for both trials. The addition of @entity1493 to TMZ and hypo-IMRT did not improve @entity1349 for @entity1 with @entity463 in two phase II trials with small @entity1 numbers; PFS was longer with @entity1493 , but the difference was not statistically significant.
